Attached files

file filename
EX-32.1 - EXHIBIT 32.1 - Checkpoint Therapeutics, Inc.v471795_ex32-1.htm
EX-31.2 - EXHIBIT 31.2 - Checkpoint Therapeutics, Inc.v471795_ex31-2.htm
EX-31.1 - EXHIBIT 31.1 - Checkpoint Therapeutics, Inc.v471795_ex31-1.htm
EX-10.2 - EXHIBIT 10.2 - Checkpoint Therapeutics, Inc.v471795_ex10-2.htm
EX-10.1 - EXHIBIT 10.1 - Checkpoint Therapeutics, Inc.v471795_ex10-1.htm
10-Q - FORM 10-Q - Checkpoint Therapeutics, Inc.v471795_10q.htm

 

Exhibit 32.2

  

Certification of

Principal Financial Officer

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

 

I, Garrett Gray, Principal Financial Officer of Checkpoint Therapeutics, Inc. (the “Company”), in compliance with Section 906 of the Sarbanes-Oxley Act of 2002, hereby certify that, to the best of my knowledge, the Company’s Quarterly Report on Form 10-Q for the period ended June 30, 2017 (the “Report”) filed with the Securities and Exchange Commission:

 

Fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

  

 

/s/ Garrett Gray 

  Garrett Gray
  Vice President, Finance and Accounting 
  (Principal Financial Officer) 
  August 9, 2017